Skip to content
Screener

Retained Earnings at other companies

Pfizer logo
PfizerPFE
$117.24B-2.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$447.96M-48.0%
CG Oncology logo
CG OncologyCGON
-$518.23M-76.4%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$650.65M-39.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$547.72M-44.9%
NTH
Neonc Technologies HoldingsNTHI
-$135.81M-53.3%

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$1.34B+59.2%
Enterprise value$1.29B+67.3%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204047
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 103,486,412 and 98,528,949 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1111
Additional paid-in capital1,143,8451,075,807
Accumulated deficit(728,009)(692,242)
Accumulated other comprehensive (loss) income(290)786
Total stockholders' equity415,557384,362
Total liabilities and stockholders' equity$436,762$408,890

Item 1. Financial Statements.

FAQ

What is Oric Pharmaceuticals, Inc.'s retained earnings?
Oric Pharmaceuticals, Inc. (ORIC) reported retained earnings of -$728.01M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
Oric Pharmaceuticals, Inc.'s retained earnings decreased by 22.8% year-over-year, from -$592.8M to -$728.01M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s retained earnings has grown at a 33.0% compound annual growth rate (CAGR), from -$166.39M to -$692.24M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Oric Pharmaceuticals, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude